Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
attrition, baseline, Connecticut, CST, culture, dialogue, difluprednate, Durezol, equally, fourth, geopolitical, hybrid, interaction, Ixo, ixoberogene, LUNA, military, mix, morale, multicenter, oral, Ozurdex, prednisone, primary, PRIME, reallocation, regimen, retaliatory, runway, soroparvovec, stable, streamline, subfield, tolerability, unforeseen, unintended, vec, virtual
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view